Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Non-GAAP disclosure centers on Adjusted EBITDA as a supplemental operating-performance measure.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Non-GAAP disclosure centers on Adjusted EBITDA as a supplemental operating-performance measure
- Management uses Adjusted EBITDA for budgeting, projections, strategy evaluation and acquisition assessment
- Investors should reconcile Adjusted EBITDA to U.S. GAAP results before assessing profitability
- Metric excludes items management considers non-core, potentially limiting comparability with GAAP earnings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.